Specialised Therapeutics signs exclusive license agreement with CanariaBio for new ovarian cancer therapy asiabulletin.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from asiabulletin.com Daily Mail and Mail on Sunday newspapers.
Independent biopharmaceutical company Specialised Therapeutics Asia Pte Ltd (ST) has signed a license deal with Korea-based CanariaBio Inc., acquiring the exclusive license to a new monoclonal antibody therapy for patients with ovarian cancer in Australia, New Zealand and in select Southeast Asian countries.
Specialised Therapeutics signs exclusive license agreement with CanariaBio for new ovarian cancer therapy malaysiasun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from malaysiasun.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Independent biopharmaceutical company Specialised Therapeutics Asia Pte Ltd (ST) has signed a license deal with Korea-based CanariaBio Inc.,.
.. First ovarian cancer therapy for ST oncology portfolio .. Phase 2 study demonstrated oregovomab in combination with chemotherapy improved progression free survival by ~30 months compared to chemotherapy alone 1 ..